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ABSTRACT
Objective: The purpose of this study was to investigate whether sevoflurane
enhances moderate dose ethanol preconditioning, and whether this additional
cardioprotection is associated with glycogen synthase kinase 3β (GSK3β), Akt,
mammalian target of rapamycin (mTOR), 70-KDa ribosomal s6 kinase 1 (p70s6K),
and/or mitochondrial permeability transition pore (MPTP) opening.
Design: In vitro study using an isolated heart Langendorff preparation.
Setting: University research laboratory.
Participants: Male guinea pigs (n=170).
Interventions: Isolated perfused guinea pig hearts underwent 30 min ischemia and
120 min reperfusion (control:CTL). The ethanol group (EtOH) received 5% ethanol in
their drinking water for 8 weeks. Anesthetic preconditioning was elicited by 10 min
exposure to sevoflurane (2%) in ethanol (EtOH+SEVO) or non-ethanol (SEVO) hearts.
Inhibition of GSK3β phosphorylation and mTOR was achieved with LY294002 and
rapamycin, respectively. GSK3β, Akt, mTOR and p70s6K expression were determined
by Western blot. Calcium-induced MPTP opening was assessed in isolated calceinloaded mitochondria.
Measurements and Main Results: After ischemia-reperfusion, EtOH, SEVO and
EtOH+SEVO had higher left ventricular developed pressure recovery and lower enddiastolic pressure versus CTL. Infarct size was reduced in EtOH and SEVO versus
CTL. EtOH+SEVO further reduced infarct size. Phosphorylation of GSK3β and Akt, but
not mTOR and p70s6K, was increased in EtOH and SEVO. Phosphorylation of GSK3β,
but not mTOR and p70s6K was further increased in EtOH+SEVO. EtOH and SEVO
reduced calcium-induced MPTP opening. EtOH+SEVO further reduced MPTP opening.
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Conclusions: Sevoflurane and chronic ethanol preconditioning offer additive
cardioprotection. This effect is associated with enhanced GSK3β phosphorylation and
inhibition of MPTP opening.

Key words: sevoflurane, preconditioning, ethanol, glycogen synthase kinase 3β,
mitochondrial permeability transition pore
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INTRODUCTION
Epidemiological studies have shown that mortality rates for people who regularly
drink ethanol in moderation are lower than in abstainers, primarily due to decreased fatal
ischemic heart disease.1 Further, moderate ethanol consumers have lower rates of myocardial
infarction compared with abstainers.2 These beneficial cardiac effects may be due to
pleiotropic effects of ethanol on lipids,3 platelets, and fibrinolytic activity.4,5 In addition,
experimental studies have revealed that light to moderate regular ethanol consumption
renders hearts more tolerant to ischemia-reperfusion injury (ethanol preconditioning)6-12,
similar to ischemic preconditioning13 in which brief episodes ischemia and reperfusion
dramatically limit infarct size following prolonged ischemia A recent study suggests that
light to moderate regular ethanol consumption in the year prior to myocardial infarction is
associated with reduced mortality following myocardial infarction.14 These findings suggest
that light to moderate ethanol consumption not only prevents myocardial infarction but also
improves survival after myocardial infarction.
Over the last 15 years, experimental and clinical studies have indicated that the use of
volatile anesthetics constitutes an additional therapeutic approach in the care of patients at
risk of developing perioperative cardiac complications, known as volatile anesthetic
preconditioning.15 It has been shown that preconditioned myocardium can also be protected
by pharmacological agents such as erythropoietin.16 volatile anesthetics17 and ethanol.18,19
We previously demonstrated that regular ethanol consumption renders hearts more tolerant
to ischemia-reperfusion injury, to a degree similar to acute ischemic preconditioning.6 We
also reported that sevoflurane enhances low dose (2.5%) ethanol-induced preconditioning
through modulation of protein kinase C (PKC), mitochondrial KATP channels (mitoKATP) and
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endothelial nitric oxide synthase (eNOS).18 However, whether sevoflurane exerts enhanced
cardioprotection at higher, clinically relevant, ethanol doses (e.g. 5%) is unknown.
Furthermore, the precise mechanisms which ultimately confer this additive cardioprotection
have not been elucidated. Growing evidence suggests that many cardioprotective signaling
pathways converge on the mitochondria to reduce cell death.20-22 Mitochondrial permeability
transition pore (MPTP) opening has been proposed as a crucial determinant of ischemiareperfusion injury.23
Ge et al. demonstrated that prevention of MPTP opening by isoflurane
postconditioning is eNOS dependent.24 Interestingly, chronic ethanol exposure has been
shown to increase eNOS expression.18
Studies have shown that inactivation of glycogen synthase kinase 3β (GSK3β) by
phosphorylation at Ser9 inhibits MPTP opening and protects cardiomyocytes.25,26 GSK3β is
inactivated by phosphatidylinositol 3-kinase (PI3K)/Akt and the mammalian target of
rapamycin (mTOR)/p70s6K pathways.27 Neznanova et al.28 reported that acute ethanol
challenge phosphorylates GSK3β in the rat prefrontal cortex. Zhou et al.29 demonstrated that
acute ethanol exposure to H9c2 cardiac cells prevents oxidant-induced MPTP opening
through inactivation of GSK3β. Inhibition of GSK3β has been also implicated in volatile
anesthetic postconditioning.30-32
These data suggest that the additive effect of sevoflurane and ethanol preconditioning
could be mediated by enhanced inhibition of MPTP opening. To date, the roles of the
Akt/GSK3β and mTOR/p70s6K pathways in cardioprotection induced by chronic ethanol
exposure has not been studied. Thus, we hypothesized that sevoflurane enhances moderate
dose (5%) ethanol-induced preconditioning and this additive cardioprotection is associated
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with 1) enhanced GSK3β inactivation, 2) Akt, mTOR or p70s6K activation and/or 3)
enhanced inhibition of MPTP opening. Elucidating mechanisms underlying the additive
cardioprotection of ethanol and sevoflurane could lead to a drug discovery to further reduce
perioperative myocardial ischemia-reperfusion injury.
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METHODS
This study was conducted in accordance with the Guidelines for Animals Research
and with the approval of the Animal Experiment Committee of Osaka Dental University,
Osaka, Japan. These guidelines conform to those laid out in the Guide for the Care and Use
of Laboratory Animals, available from the National Academy of Science.33 Male Hartley
guinea pigs were fed Lab Diet (RC4, Oriental Yeast, Tokyo, Japan) and given water ad
libitum.
Male guinea pigs weighing 300-350g (3-4 weeks old) were initially given 1.25%
ethanol in their drinking water for 1 week, 2.5% for 1 week then 5% for 8 weeks (ethanol
group: EtOH). Control group was treated with drinking water for 10 weeks (CTL). After
treatment, animals (550-700g, 13-14 weeks old) were given heparin (1000 units
intraperitoneally), then anesthetized with pentobarbital (60 mg/kg, intraperitoneally). Hearts
were excised and immediately arrested in cold iso-osmotic saline containing 20 mM KCl.
The aorta was cannulated and the isolated hearts were perfused at 70 mmHg on a
nonrecirculating isovolumic perfused heart apparatus, using a Krebs-Henseleit perfusate and
paced at 240 beats/min as previously described.32 Serum ethanol levels at time of sacrifice
were measured by gas chromatography (Shimadzu, Kyoto, Japan). Liver enzymes were
measured to rule out possible liver tissue damage. Sevoflurane was insufflated by passing
the 95%O2/5%CO2 gas mixture through a calibrated vaporizer (ACOMA, Tokyo, Japan).
Samples of coronary perfusate were collected anaerobically from the aortic cannula for
measurement of sevoflurane concentration by an organic vapor sensor (OSP, Saitama,
Japan).
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Animals were assigned to one of 8 groups (n=8 each; Figure 1). After a 20 min
equilibration, baseline left ventricular developed (LVDP; mmHg) and end-diastolic
(LVEDP; mmHg) pressures, and coronary flow (CF; mlmin-1g-1) were recorded. Control
and EtOH groups were subjected to 30 min of ischemia followed by 120 min of reperfusion.
Anesthetic preconditioning was elicited by administration of sevoflurane (2%) for 10 min
followed by 10 min washout before 30 min of ischemia followed by 120 min of reperfusion
(SEVO). To investigate whether sevoflurane enhances ethanol preconditioning, ethanoltreated hearts were subjected to the identical protocol of SEVO group (EtOH+SEVO).
To investigate the role of GSK3β, its upstream, PI3K inhibitor, LY294002 (Cayman
Chemical, Ann Arbor, MI) or saline as a vehicle were administered starting 5 min before
sevoflurane exposure and throughout the reperfusion period in EtOH, SEVO, EtOH+SEVO
and CTL groups (EtOH+LY, SEVO+LY, EtOH+SEVO+LY, CTL+LY). LY294002 was
dissolved in ethanol (0.03%), and added to the KH perfusate to a final concentration of 15
M. To investigate the involvement of mTOR and p70s6K in EtOH hearts treated with
sevoflurane, rapamycin (100nM, Sigma ALDRICHI, St. Louis, MO) or saline as a vehicle
were administered starting 5 min before sevoflurane exposure and throughout the
reperfusion period in CTL and EtOH+SEVO groups (CTL+Rapa, EtOH+SEVO+Rapa).
These doses of LY294002 and rapamycin were previously reported to effectively inhibit
PI3K and mTOR, respectively.34,35 We performed experiments in the following order (with
the laboratory investigator performing the experiments blinded to the groups): first a CTL,
followed by ETOH, SEVO, ETOH+SEVO, and so forth until the first series of experiments
were completed. The experiments using LY294002 and rapamycin were done in the same
manner.
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At the end of experiments, the hearts were quickly frozen at –80 °C for 15 min, then
sliced into 2 mm thick transverse sections from apex to base (6 slices/heart). Each slice was
weighed and incubated at 37 °C with 1% triphenyltetrazolium chloride (Sigma ALDRICHI)
in phosphate buffer (pH 7.4) for 10 min and then fixed in 10% formalin for at least 5 h to
distinguish red stained viable tissue from pale unstained necrotic tissue.36 Infarct size was
determined using Adobe Photoshop® CS4 (Adobe, San Jose, USA) as previously
described.32
Separate experiments were performed (n=4 in each group) to examine expression of
Akt, mTOR, p70s6K and GSK3β. For this purpose, different hearts from infarct size study
were used. Myocardial tissue samples were collected at 5 min after reperfusion, and
homogenized in ice-cold homogenizing buffer with protein samples and membranes
prepared as previously described.32 After blocking with 5% skim milk in Tris-buffered
saline containing 0.1% Tween-20 (TBS-T), the membranes were incubated for 2 h at 4 °C in
TBS-T containing 5% milk and overnight 1:500-1000 dilution of rabbit primary antibody
for phospho Akt (Ser47), mTOR (Ser2448), p70s6K (Thr389) and GSK3β (Ser9) (Cell
Signaling TECHNOLOGY, Boston, USA). Membranes were incubated with a 1:1000
dilution of horseradish peroxidase–labeled anti-rabbit immunoglobulin G (NA 934V, GE
Healthcare, Buckinghamshire, UK). The same blot was stripped and re-blotted with
antibodies to -tubulin (to confirm equal protein loading), total Akt, mTOR, p70s6K and
GSK3β (Cell Signaling TECHNOLOGY). Bound antibody signals were detected with
enhanced chemiluminescence (Pierce Biotechnology, Rockford, USA) and visualized using
VersaDoc 5000 Imaging System (Bio-Rad, Hercules, USA). Quantitative analysis of the
band densities was performed by Quantity One software (Bio-Rad) as previously
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described.37
To investigate the involvement of MPTP in enhanced cardioprotection, mitochondria
were isolated from guinea pig hearts (n=4 for each group). For this purpose, different hearts
from infarct size study were used. After perfused and exposed to sevoflurane and inhibitors,
isolated hearts were removed from the Langendorff apparatus and homogenized in ice-cold
MSTEB buffer as previously described.37 The extracted mitochondria were diluted in icecold respiratory buffer and incubated with 1μM calcein-AM (Invitrogen Molecular Probes,
Carlsbad, USA) for 15 min at room temperature. Calcein-AM readily enters the
mitochondria and is trapped in the matrix in its free form, which is fluorescent. After calcein
was trapped in mitochondria, the mitochondria were washed by KCl buffer as previously
described.37 Calcein-loaded mitochondria were treated with 50 and 150 μM Ca2+ per
milligram of protein, and were incubated for 10 min at room temperature. Then
mitochondrial fluorescences were acquired. Flow cytometric analysis was performed on
FACS calibur™ (Becton Dickinson, Franklin lakes, USA). Mitochondria labeled with
calcein-AM were analyzed by flow cytometry in an instrument equipped with a 488 nm
excitation source.
Statistical power analysis revealed that a sample size of n=8 would provide sufficient
power (0.8) to detect a difference between mean infarct size indices of 15 % (SD=9, α=0.05).
A group size of n=4 was used for Western blot and calcein studies to provide a power of 0.8
to detect a difference between means of 20% (SD=10, α=0.05). Hemodynamic data were
tested for normal distribution and subsequently analyzed by a two-factor repeated-measures
analysis of variance for time and treatment. If an overall difference between the variables
was observed, comparisons were performed as one-way ANOVA followed by Tukey's post-
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hoc test for inter-group differences and by Dunnett's for intra-group differences with
baseline values as the reference time point. Analysis of infarct size, Western blot and
mitochondrial calcein fluorescence was performed using one-way ANOVA followed by
Student's t-test with Bonferroni's correction for multiple comparisons to avoid type I error.
For changes within and between groups a two-tailed p value less than 0.05 was considered
significant in advance. (SPSS17 for Windows, SPSS Japan, Tokyo, Japan).
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RESULTS
Of a total of 170, 10 hearts were not used secondary to intractable ventricular
fibrillation after reperfusion (mortality rate was not different among groups) and one heart
was not used due to aortic rupture. Additional hearts were studied until each group had n=8
successful experiments. There was no significant difference in body weight among groups.
Serum ethanol level at time of sacrifice was 3.5±2.7 mM. As a comparison, the minimum
blood alcohol concentration associated with intoxication in humans is 8 mM (40 mg/dl or
0.04%). Ethanol was not detected in the effluent of the 10 EtOH hearts sampled after 50 min
washout. There was no difference in liver enzymes levels between EtOH and CTL animals.
The concentration of sevoflurane in the coronary perfusate after 10 min of exposure was
0.27±0.02 mM.
Myocardial infarct size in EtOH and SEVO were significantly reduced compared
with CTL (EtOH:24±8%, SEVO:23±6% vs. CTL:41±6%, p<0.05). The administration of
sevoflurane in EtOH hearts further decreased infarct size compared with EtOH alone
(EtOH+SEVO:10±4%, vs. EtOH: 24±8%, p<0.05). This reduction of myocardial infarct size
in

EtOH+SEVO

was

abolished

by

LY294002,

but

not

by

rapamycin

(EtOH+SEVO+LY:31±3%, p=0.188, EtOH+SEVO+Rapa:17±5%, p<0.05, vs. CTL).
Treatment with LY294002 alone did not affect the infarct size compared with CTL, though
treatment with rapamycin alone did reduce infarct size (CTL+Rapa: 27±9%, p<0.05, vs.
CTL) (Fig 2).
Baseline LVDP and CF were similar among the 8 groups. Administration of
sevoflurane or treatment with LY294002 and rapamycin did not significantly affect LVDP or
CF before ischemia. After 120 min reperfusion, recovery of LVDP was greater in EtOH,
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SEVO, EtOH+SEVO and CTL+Rapa compared with CTL. Recovery of LVDP in
EtOH+SEVO hearts was abolished by administration of LY294002, but not rapamycin.
Treatment with LY294002 or rapamycin alone did not adversely affect recovery of LVDP.
LVEDP increased to 600% of baseline in CTL after ischemia-reperfusion. The increase in
LVEDP was significantly less in EtOH, SEVO, EtOH+SEVO and CTL+Rapa compared
with CTL. Of note, LVEDP in LY294002 treated groups was lower compared with CTL, but
not compared with EtOH, SEVO or EtOH+SEVO. There was no significant difference in CF
among all groups throughout the experiment. This suggests that changes in CF could not
account for the improved contractile recovery of EtOH, SEVO, ETOH+SEVO hearts (Table
1).
Total Akt and GSK3β were comparable in all samples. The ratio of phospho Akt to
total Akt and phospho GSK3β to total GSK3β was significantly increased in EtOH and
SEVO compared with CTL. This increase was not caused by unequal loading of the western
blot, as shown by the detection of -tubulin. The combination of ethanol and sevoflurane
enhanced this increased expression of phospho GSK3β in EtOH+SEVO. Administration of
LY294002, but not rapamycin, abolished this enhanced expression of phospho GSK3β in
EtOH+SEVO. Treatment with rapamycin alone increased phospho Akt and phospho GSK3β
expressions. The ratio of phospho mTOR to total mTOR and phospho p70s6K to total
p70s6K was not increased in CTL, EtOH and SEVO. However, it was significantly increased
in EtOH+SEVO compared with other groups. This increase was abolished by rapamycin
(Fig 3).
The mitochondrial calcein fluorescence values after treatment with Ca2+ were taken
as the values from which any reduction in fluorescence was measured. Exposure of
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mitochondria to 50 μM Ca2+ did not induce MPTP opening in any groups (Fig 4A). However,
exposure of mitochondria to 150μM Ca2+ induced MPTP opening, represented by a
reduction in calcein fluorescence of -59.3±12.1% in CTL. This Ca2+-induced reduction was
attenuated in EtOH and SEVO (-37.9±11.9%; p<0.05, -26.9±8.1%; p<0.05, respectively, vs.
CTL) (Fig 4B). This effect was enhanced by the combination of ethanol and sevoflurane
(EtOH+SEVO: -3.0±9.9%; p<0.05 vs. EtOH and SEVO), which was abrogated by treatment
with LY294002 (-60.4±9.3%), but not rapamycin (-16.4±19.2%; p<0.05 vs. CTL). Treatment
with rapamycin alone slightly attenuated reductions in fluorescence of CTL, but this effect
did not reach statistical significance (CTL+Rapa: -48.5±9.4%) (Fig 4C).
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DISCUSSION
Sevoflurane confers additive cardioprotection to moderate dose ethanol-induced
preconditioning. Further, this cardioprotective effect is associated with enhanced
phosphorylation/inhibition of GSK3β and inhibition of MPTP opening. We previously
demonstrated that exposure to 2.5% (low dose) ethanol for 6 weeks reduces ischemiareperfusion injury to the same degree as 5%, 10%, and 20% ethanol for 6 to 12 weeks.6 We
also found that sevoflurane enhances low dose ethanol-induced preconditioning.18 The
present study suggests that sevoflurane enhances cardioprotection afforded by ethanol
preconditioning at a higher level of exposure, equivalent to moderate ethanol consumption. It
has been reported that the combination of two preconditioning stimuli enhances
cardioprotection afforded by either stimulus alone.16,18,19,38 The present study demonstrated
that the combination of moderate ethanol consumption and sevoflurane exposure enhanced
inhibition of MPTP opening associated with enhanced GSK3β phosphorylation through both
PI3K-Akt and mTOR/p70s6K pathways.
Nishihara

et

al.
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demonstrated

that

erythropoietin

affords

additional

cardioprotection to ischemic preconditioning by enhanced phosphorylation of GSK3β in in
vivo rabbit hearts, but involvement of MPTP opening was not investigated. Zhou et al.29
demonstrated that acute ethanol exposure to H9c2 cardiac cells prevented oxidant-induced
MPTP opening through inactivation of GSK3β.
It is now widely recognized that MPTP opening is a major cause of myocardial cell
death after reperfusion and a target for cardioprotection.21 Under physiological conditions,
MPTP is predominantly in a closed state. The opening of MPTP is increased by calcium
overload due to ischemia, ATP depletion, accumulation of inorganic phosphate and burst
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production of reactive oxygen species (ROS) immediately after reperfusion. This MPTP
opening results in depolarization of the mitochondrial membrane potential and matrix
swelling.39,40 Although acute ethanol exposure to H9c2 cardiac cells has been shown to
prevent ROS-induced MPTP opening,29 whether chronic ethanol consumption prevents
calcium-induced MPTP opening has not been investigated. The present study addressed the
susceptibility of MPTP opening after Ca2+ loading in isolated mitochondria from hearts that
were chronically exposed to moderate ethanol. Furthermore, acute sevoflurane exposure to
ethanol-treated mitochondria enhanced the inhibition of MPTP opening. Exposure of
mitochondria to 150 μM Ca2+, not 50 μM Ca2+, induced MPTP opening in control hearts,
represented by reduction in calcein fluorescence. This reduction was attenuated in
mitochondria from ethanol and sevoflurane exposed hearts, and to an even greater degree in
mitochondria from hearts exposed to both moderate ethanol and sevoflurane.
The threshold for MPTP opening is elevated by phosphorylation of GSK3β at Ser9,
which inactivates this kinase.26 In turn, GSK3β has been shown to be inactivated by
PI3K/Akt and mTOR/p70s6K pathways.27 In the present study, ethanol or sevoflurane alone
increased GSK3β phosphorylation through Akt activation, but not mTOR/p70s6K.
Interestingly, the combination of ethanol and sevoflurane activated both pathways, leading to
enhanced phosphorylation of GSK3β. The role of mTOR in cardioprotection remains
controversial. Studies have demonstrated a protective effect of rapamycin, an mTOR
inhibitor.41 A recent study demonstrated that cardioprotection by ischemic preconditioning
involves both mTOR and Wnt pathways, placing mTOR downstream of GSK3β.42 In the
present study, phosphorylation of both GSK3β and mTOR was seen in only EtOH+SEVO,
which was abolished by LY294002. This suggests that PI3K/Akt and GSK3β are important
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mediators of this additive cardioprotection. Rapamycin failed to abolish the enhanced
inhibition of MPTP opening and reduction of infarct size in EtOH+SEVO. However,
rapamycin has been shown to protect the heart against ischemia-reperfusion injury through
Akt activation.35,41 This is consistent with the present study as seen in CTL+Rapa group. The
combination of EtOH and sevoflurane may activate additional cardioprotective signaling
pathways and mTOR may not be essential for inhibition of MPTP. The exact relationship
between GSK3β and mTOR remains unclear, as there is currently no drug available to
directly inhibit phosphorylation/inactivation of GSK3β. mTOR consists of two functionally
distinct complexes, that is, mTOR complex 1 and complex 2. A component of mTOR
complex 2, Rictor (rapamycin-insensitive associated protein of mTOR) has been implicated
in activating cell survival.43 Recently, ethanol has been shown to increase the activity of
mTOR complex 2 in myoblast.44 The potential mechanisms of enhanced cardioprotection by
the combination of ethanol and sevoflurane found in this study are summarized in Figure 5.
The following study limitations should be acknowledged. First, in order to more fully
mimic the clinical setting, sevoflurane should be administered throughout experiments.
However, our previous study has shown that a brief exposure to the heart is as effective as
continued administration of sevoflurane.32 Second, we utilized isolated mitochondria
exposed to high concentrations of Ca2+ to evaluate MPTP opening susceptibility in vitro. A
previous study demonstrated that the amount of Ca2+ required to induce MPTP opening
depends on the experimental conditions such as the presence of adenine nucleotides in the
medium.45 Although we cannot the possibility that our results may not accurately reflect the
conditions experienced by in vivo mitochondria during ischemia-reperfusion,46 our primary
purpose was to assess the susceptibility of MPTP opening in isolated mitochondria exposed
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to ethanol and sevoflurane. Third, GSK3β is a substrate for multiple pro-survival protein
kinases, including Akt, ε-PKC, extracellular signal-regulated kinase 1/2 and protein kinase
G27. We cannot exclude the possibility that kinases other than PI3K/Akt and mTOR/p70s6K
pathways may contribute to enhanced phosphorylation of GSK3β by ethanol and sevoflurane.
Fourth, Krenz et al. demonstrated that acute (as opposed to chronic) ethanol exposure fails to
exert cardioprotection when ethanol is present during ischemia-reperfusion.47 Although not
withdrawn from the drinking water before sacrifice in the present study, serum ethanol levels
were low (3.5 mM) at the time of sacrifice, and no ethanol was present in the perfusate at the
time of ischemia-reperfusion.
In conclusion, sevoflurane enhances cardiac preconditioning induced by moderate, as
well as, low dose ethanol consumption. This effect may be mediated by preventing MPTP
opening through convergence of protective signaling on GSK3β phosphorylation/inhibition.
Because volatile anesthetics can be administrated with relatively low toxicity, elucidating the
mechanisms underlying ethanol and volatile anesthetic-induced preconditioning could
hopefully lead to therapies to reduce perioperative myocardial ischemia-reperfusion injury.
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Figure legends
Figure 1: Schematic illustration of the experimental protocol of this study. All hearts were
subjected to 30 min global ischemia followed by 120 min reperfusion. Anesthetic
preconditioning was elicited by administration of sevoflurane (2% or 1 MAC) for 10 min
with a 10 min washout period. Ethanol-treated animals were initially given 1.25% ethanol in
their drinking water for 1 week, 2.5% for 1 week then 5% for 8 weeks. Tissue samples were
obtained at 10 min after reperfusion. CTL=control; EtOH=ethanol; SEVO=sevoflurane;
LY=LY294002, PI3/Akt inhibitor; Rapa=rapamycin, mammalian target of rapamycin
(mTOR) inhibitor.

Figure 2: Infarct size as a percentage of LV in eight groups. Treatment with sevoflurane (1
MAC) and 5 % ethanol for 8 weeks equally reduced infarct size compared with control. The
combination of sevoflurane and 5 % ethanol conferred a further reduction of infarct size.
This additional cardioprotective effect was abolished by LY294002, but not by rapamycin,
in SEVO+EtOH. LY204002 treatment alone did not affect infarct size. Data are presented as
mean ± SD. #p<0.05 vs. CTL, †p<0.05 vs. EtOH and SEVO

Figure 3: (A, B) Representative western blot of phospho Akt and phospho GSK3β from left
ventricular samples acquired at 5 min after reperfusion (n=4 for each group). Expression of
phospho Akt and phospho GSK3β was significantly increased in EtOH and SEVO. The
combination of ethanol and sevoflurane enhanced this increased expression of phospho
GSK3β in EtOH+SEVO. Administration of LY294002 abolished this enhanced expression of
phospho GSK3β in EtOH+SEVO. However, administration of rapamycin failed to abolish this
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enhanced expression. (C, D) Representative western blot of phospho mTOR and p70s6K from
left ventricular samples acquired at 5 min after reperfusion (n=4 for each group). Expression
of phospho mTOR and phospho p70s6K was not increased in CTL, EtOH and SEVO.
However, the combination of ethanol and sevoflurane increased phospho mTOR and phospho
p70s6K. Both LY294002 and rapamycin abolished this enhanced expression of phospho
mTOR and p70S6K in EtOH+SEVO.
Densitometric evaluation of four experiments as the x-fold increase in average light density
(AVI) vs. CTL. The results are presented as the ratio of phosphorylation state to total protein.
The average light intensity was multiplied by 100 to facilitate presentation of an x-fold
increase. Data are meanSD. *p<0.05 vs. CTL, #p<0.05 vs. EtOH and SEVO

Figure 4: Representative flow cytometric profile of isolated cardiac mitochondria loaded
with calcein showing the effects of calcium on mPTP opening as demonstrated by reductions
in mitochondrial calcein fluorescence. (A) Exposure of mitochondria to 50 μM Ca2+:
Reductions in mitochondrial calcein fluorescence were not seen in any groups. (B, C)
Exposure of mitochondria to 150μM Ca2+ induced MPTP opening in CTL. This Ca2+induced reduction in calcein fluorescence was attenuated in EtOH and SEVO. This effect
was enhanced in EtOH+SEVO, which was abrogated by treatment with LY, but not
rapamycin. (D) Effect of calcium (150μM) on MPTP opening as demonstrated by reductions
in mitochondrial calcein fluorescence. Mean±SD percent change from control in the
presence or absence of LY (15 μM) and rapamycin (100nM). *p<0.05 vs. CTL, #p<0.05 vs.
EtOH, SEVO, n=4 for each group
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Figure 5: Schematic diagram of the preconditioning cardioprotection conferred by ethanol
and sevoflurane. Phosphorylation of GSK3β by PI3-Akt or mTOR-p70s6K pathway inhibits
MPTP opening. Treatment with ethanol or sevoflurane alone activates the PI3-Akt pathway,
but not the mTOR-p70s6K pathway. Simultaneous activation of these two pathways is
achieved by the combination of ethanol and sevoflurane, but not by ethanol or sevoflurane
alone. This activation of dual pathways enhances GSK3β phosphorylation and elevates the
threshold of MPTP opening achieved by ethanol or sevoflurane alone. Rapamycin failed to
abolish enhanced cardioprotection by the combination of ethanol and sevoflurane. This may
be due to mTOR complex 2 which is rapamycin-insensitive. PI3K = phosphatidylinositol 3kinase; Akt = protein kinase B; GSK3β = glycogen synthase kinase 3β; mTOR; mammalian
target of rapamycin; p70S6K = 70-KDa ribosomal s6 kinase; MPTP = mitochondrial
permeability transition pore.
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